The estimated Net Worth of Raj Mehra is at least $761 Tausend dollars as of 1 December 2023. Dr Mehra owns over 75,757 units of Seelos Therapeutics stock worth over $37,028 and over the last 5 years he sold SEEL stock worth over $0. In addition, he makes $724,234 as Founder, Chairman und CEO & Pres at Seelos Therapeutics.
Dr has made over 3 trades of the Seelos Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 75,757 units of SEEL stock worth $99,999 on 1 December 2023.
The largest trade he's ever made was buying 133,333 units of Seelos Therapeutics stock on 13 February 2020 worth over $100,000. On average, Dr trades about 30,640 units every 154 days since 2020. As of 1 December 2023 he still owns at least 185,142 units of Seelos Therapeutics stock.
You can see the complete history of Dr Mehra stock trades at the bottom of the page.
Dr. Raj Mehra J.D., Ph.D. is the Founder, Chairman, CEO & Pres at Seelos Therapeutics.
As the Founder, Chairman und CEO & Pres of Seelos Therapeutics, the total compensation of Dr D at Seelos Therapeutics is $724,234. There are 1 executives at Seelos Therapeutics getting paid more, with Richard Pascoe having the highest compensation of $917,292.
Dr D is 61, he's been the Founder, Chairman und CEO & Pres of Seelos Therapeutics since . There are no older and 4 younger executives at Seelos Therapeutics.
Raj's mailing address filed with the SEC is C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 2ND FLOOR, NEW YORK, NY, 10022.
Over the last 6 years, insiders at Seelos Therapeutics have traded over $0 worth of Seelos Therapeutics stock and bought 409,757 units worth $387,856 . The most active insiders traders include Brian Lian, Raj Mehra und Robin L Smith. On average, Seelos Therapeutics executives and independent directors trade stock every 231 days with the average trade being worth of $13,659. The most recent stock trade was executed by Raj Mehra on 1 December 2023, trading 75,757 units of SEEL stock currently worth $99,999.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
Seelos Therapeutics executives and other stock owners filed with the SEC include: